KRPIA urges incoming Assembly to recognise new drugs’ value

28 May 2024 - The Korean Research based Pharma Industry Association (KRPIA) called for the 22nd National Assembly, which is ...

Read more →

Has the Centers for Medicare Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations?

15 December 2023 - The US Inflation Reduction Act of 2022 created several major policy changes to the pricing of prescription ...

Read more →

A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier

6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 ...

Read more →

An alternative measure of health for value assessment: the equal value life-year

10 September 2023 - The quality-adjusted life-year (QALY) is an international standard in cost-effectiveness analysis. A known concern arises from the ...

Read more →

Do France, Germany, and Italy agree on the added therapeutic value of medicines?

17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...

Read more →

Added therapeutic benefit of top selling brand name drugs in Medicare

18 April 2023 - What was the added therapeutic benefit of the 50 top selling drugs in Medicare in 2020, ...

Read more →

Cost effectiveness thresholds used by study authors (1990-2021)

18 April 2023 - For decades, many US authors of cost effectiveness analyses referenced a common benchmark or threshold—$50 000 per quality-adjusted ...

Read more →

NICE’s new methods reflect society’s values

4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...

Read more →

Association between US drug price and measures of efficacy for oncology drugs approved by the US FDA from 2015 to 2020

31 October 2022 - The past five years have seen a marked increase in the number of cancer therapies on the ...

Read more →

Drugs should be priced based on one factor – value

20 October 2022 - For a number of years, the price of drugs has drawn extraordinary attention.  ...

Read more →

From scientific discovery to covered treatments: understanding the payer perspective as a keystone to achieving high value care

26 May 2022 - The mission of the National Institutes of Health is to translate scientific discovery into health by designing ...

Read more →

The Center for Medicare and Medicaid Innovation - toward value based care

9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...

Read more →

Consensus lacking on ‘value’ for new anti-cancer drugs

8 December 2021 - The high price tag of new anticancer drugs has fuelled debate about the value of these treatments, ...

Read more →

Drug pricing debate redux — should cost effectiveness analysis be used now to price pharmaceuticals?

13 November 2021 - The idea of permitting the government to negotiate pharmaceutical prices raises a question about the basis for ...

Read more →

Paying for cancer drugs that prove their benefit

11 October 2021 - The United States pays prices for brand name drugs that are estimated to be 256% higher than ...

Read more →